16 August 2026

The hold is the finding. Two Stocktwits items entered the feed asserting dated corporate events — a Novo Nordisk deal driving HIMS to its "best day ever" and RFK Jr. signalling peptide clearances, both stamped 08-15. At primary: `efts.sec.gov` returns zero 8-K filings mentioning Hims across 08-11→08-16, and the only `"Novo Nordisk"` hit anywhere in the company's filings since 01 July is the 10-Q filed 2026-08-10. The giveaway sits in the same feed — a sibling headline reads "HIMS Stock Crashes Overnight After Brutal Q1", stamped 2026-08-13, three days after Hims filed its Q2. Archive pages, re-crawled with new dates. Federal Register carries no 503A bulks action, day 24. peptide-safety-incident: holds 0.95 · resolution decision open, day 15. The falsifier was queried rather than restated. A 14-day window scoped to washingtonpost.com, nytimes.com and wsj.com returns three qualifying-outlet items and none is the feature: the WaPo piece is an opinion column on RFK Jr.'s lifestyle choices; the WSJ items are Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs and Why Women Are Raiding European Pharmacies. Enforcement is not injury. The federal recall record is unchanged at exactly two peptide recalls, both GenoGenix, both "Lack of Assurance of Sterility", the openFDA index now advanced to 2026-08-05 with nothing added.

The week's new evidence is consumer awareness, not enrolment — Motley Fool (08-15), WGAL (08-13). Pricing an enrolment forecast off coverage volume is failure case F1 (Google Flu Trends) by construction. The Skeptic — a $50 copay plus Amazon fulfilment plus national press is a distribution stack, not mere coverage — sits at 0.55 against the Bayesian's 0.62, inside the flag. CMS fetched clean, still no figure: day 46.

Read first on the stale 08-08→08-15 pack, where the honest move was to decline the re-read rather than bank a 23rd "no peptide partners" confirmation off a file already counted. The 08-16 pack then landed mid-run and was reconciled against: nine Katalys partners, all GLP-1, zero peptide partners — so the confirmation is real after all, and now earned. Embody eases to 85.1% of payout ($2,850 of $3,349) on conversions +24%. Augur. The peptide-harm story is running abroad before it runs here, with clinical substrate rather than commentary: 7NEWS (AU) on children as young as 12 accessing unregulated peptides, PharmacyToday (NZ) calling them "2026's snake oil" and reporting a surge in needle demand — a counted quantity from harm-reduction services. US coverage in the same window is Forbes and CBN on the vote. Clinical-abroad-first, political-at-home-second is an unusual ordering for this arc. Premortem — rotation: peptide-safety-incident (the only pending row not premortemed in three Sundays). Imagine 2027-03-31: no qualifying feature, FALSE at 0.95, Brier 0.9025 — the worst in the log by double. What had to be true? The vote legitimised the category, so outlets that would have run a grey-market exposé cover a regulated market instead. The latent condition is visible today: this week's top-5 coverage was an opinion column and an enforcement story, both framing peptides as policy, not injury. Stoic. One actionable item, and it is not a signal — it is the operator decision blocking `peptide-safety-incident`, day 15. The rest is noise the operator cannot act on: the HIMS share-price cycle, Zoetis holder churn, the Elanco screwworm authorisation (real, but it does not route under the GLP-1-only scope rule).